摘要
Abstract
OBJECTIVE: To evaluate the efficacy and safety of etanercept in the treatment of moderate-to-severe plaque psoriasis. METHODS: We searched the MEDLINE (1966 to Apr. 2011) , Cochrane Library (No. 4 in 2011) , Embase(1974 to Apr. 2011), ISK1961 to Apr. 2011), CNKI (1979 to Apr. 2011), CBM (1978 to Apr. 2011) and VIP (1989 to Apr. 2011)to collect randomized controlled trials (RCTs) of etanercept for psoriasis. The languages were confined to English and Chinese. We screened the retrieved studies according to the predefined inclusion and exclusion criteria, evaluated the quality of included studies, and performed Meta-analysis by RevMan 5.0 software. RESULTS: 5 RCTs were included, involving 2 107 patients with chronic moderate-to-severe plaque psoriasis. The Meta-analysis showed 12 weeks after subcutaneous injection with etanercept, PASI 75 was obviously higher than those of placebo groups [RR= 11.31, 95% CI (6.61, 19.34)] (25 mg, twice a week or 50 mg once a week), [RR=11.92, 95%CI(8.17, 17.39)] (50 mg, twice a week). There were statistical significance in the incidence of injection-site adverse events between etanercept group and placebo group [RR=2.31, 95%CI(1.63,3.28)]. There was no statistical significance in the incidence of serious adverse events (SAEs) between etanercept group and placebo group [RR=1.06,95%CI(0.58,1.95)]. CONCLUSION: Clinical trial data indicates that subcutaneous injection of etanercept is safe and efficient for patients with moderate-to-severe plaque psoriasis.关键词
2型糖尿病/艾塞那肽/胰岛素/血糖/不良反应Key words
Etanercept/Psoriasis/Randomized controlled trials/Systematic review分类
医药卫生
